Do Cannabinoids Actually Work for MS? A Skeptical Assessment of 2004 Evidence | Research

The takeaway

A critical review noted that despite exciting receptor and animal model research, only 10 clinical reports with 78 patients existed, and better-designed studies had failed to demonstrate objective improvement in MS spasticity.

Read this if you want a balanced, skeptical assessment of the evidence for cannabis in MS from 2004.

Only 78 MS patients worldwide in clinical reports; objective evidence still lacking

What the researchers found

While the identification of cannabinoid receptors and endocannabinoid ligands, along with animal model efficacy, generated excitement about cannabinoid treatment for MS, the clinical evidence was described as equivocal. Only ten published clinical reports involving 78 individuals worldwide existed, and the results were mixed.

From the studies specifically examining spasticity, the somewhat better-designed ones failed to demonstrate objective improvement. The authors noted that researchers faced significant difficulties in designing clinical studies with cannabinoids, including blinding challenges and outcome measure selection. The review characterized the overall evidence as "still lacking" for convincing demonstration of cannabinoid efficacy in MS.

Why it matters

This review provided a necessary counterpoint to the often optimistic framing of cannabinoid research. By highlighting the gap between receptor biology enthusiasm and clinical trial results, it reinforced the importance of rigorous evidence standards and identified specific challenges that needed to be addressed.

The numbers in context

Ten published clinical reports involving 78 individuals worldwide. Better-designed studies failed to show objective improvement.

How the study worked

This was a narrative review critically assessing the clinical evidence for cannabinoids in MS, published in the pharmacology journal Drugs, covering receptor biology, animal models, and clinical trial results.

What this study cannot tell us

The review was published before many larger trial results were available. The critical stance may have underweighted patient-reported benefits. The focus on objective measures aligned with traditional evidence standards but may not have captured the full clinical picture.

How to read the evidence

This is a critical narrative review in a pharmacology journal providing moderate-level evidence through honest assessment of a limited evidence base.

When this study was published

Published in 2004. Sativex was subsequently approved for MS spasticity, partially addressing the evidence gaps identified here.

The bigger picture

The skepticism expressed here was partially addressed by subsequent larger trials and the development of patient-reported outcome measures. However, the fundamental challenge of demonstrating objective spasticity improvement with cannabinoids has persisted, with Sativex approval ultimately relying on a combination of objective and subjective measures.

Questions still open

Were the difficulties in demonstrating objective improvement due to inadequate outcome measures or genuine lack of efficacy? Has subsequent evidence resolved the skepticism expressed here?

Common questions

Why were researchers struggling to prove cannabis works for MS?

Several challenges were identified: difficulty blinding participants (patients could tell they were getting cannabis), choosing appropriate outcome measures (standard scales did not capture what patients experienced), and the small number of studies available at the time.

Has the evidence improved since 2004?

Yes. Larger trials (including the 667-patient CAMS study and the MUSEC trial), along with the development of better outcome measures, eventually provided sufficient evidence for Sativex to be approved for MS spasticity in multiple countries.

Read the original research

Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Drugs, 64(1), 1-11

View on PubMed ↗

Citation

Killestein, Joep; Uitdehaag, Bernard M J; Polman, Chris H. (2004). Cannabinoids in multiple sclerosis: do they have a therapeutic role?. Drugs, 64(1), 1-11.